Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma—A New Disease Biomarker?

Keßler, Almuth F.; Schmitt, Dominik; Salvador, Ellaine; Monoranu, Camelia; Feldheim, Jonas; Ernestus, Ralf‐Ingo; Löhr, Mario; Hagemann, Carsten

doi:10.3390/cancers12051085

Cited by 23 publications

(27 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggest that MPS-1 plays a role in endometrioma progression, which may contribute to explore the pathogenesis of endometrioma. MPS-1 is secreted from hyperplastic tissues and can be detected in the serum [23]. MPS-1 is elevated in numerous types of cancer, including breast cancer, lung cancer, and head and neck squamous cell carcinoma [10].…”

Section: Discussionmentioning

confidence: 99%

Overexpressed MPS-1 contributes to endometrioma development through the NF-κB signaling pathway

Liu

Zhang

et al. 2021

Reprod Biol Endocrinol

View full text Add to dashboard Cite

Background Endometriosis is a benign gynecological disease that shares some characteristics with malignant tumors and affects approximately 10% of women of reproductive age. Endometrioma refers to endometriosis that appears in the ovary. Metallopanstimulin-1 (MPS-1) is a component of the 40S subunit of ribosomes that has extra-ribosomal functions that contribute to the development of diseases. This study aimed to explore the expression pattern and role of MPS-1 in endometrioma development. Methods Quantitative real time polymerase chain reaction, western blotting, immunohistochemistry, and enzyme-linked immunosorbent assay were used to determine the expression of MPS-1 in patients with endometrioma. Following the successful knockdown of MPS-1 by siRNA, CCK-8 assays, flow cytometry, and transwell assays were performed to detect ectopic endometrial stromal cells (EcESCs) proliferation, the rate of apoptosis, and cell cycle, migration, and invasion, respectively. Western blotting was used to explore the effect of MPS-1 knockdown on protein levels in the NF-κB signaling pathway. Results The expression of MPS-1 was significantly higher in endometrioma and the serum of endometrioma patients than in the patients without endometriosis. In addition, the downregulation of MPS-1 expression inhibited EcESCs proliferation, migration, and invasion. This downregulation led to the arrest of the EcESCs cycle in the G0/G1 phase and apoptosis and depressed the NF-κB signaling pathway. Conclusion MPS-1 can regulate EcESCs proliferation, motility, invasion, apoptosis, and cell cycle via the NF-κB signaling pathway in endometrioma. This may contribute to the formation or development of endometriotic foci. This study suggests the potential role of MPS-1 in the pathogenesis of endometriosis and enabled further research into the use of MPS-1 in the clinical diagnosis of endometrioma.

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpressed MPS-1 contributes to endometrioma development through the NF-κB signaling pathway

Liu

Zhang

et al. 2021

Reprod Biol Endocrinol

View full text Add to dashboard Cite

show abstract

“…Hegi et al, also reported that combined TMZ plus RT as compared to RT alone in the unmethylated group yielded a signi cantly prolonged PFS statistically, and combined TMZ plus RT as compared to RT alone in the unmethylated group prolonged OS, although the differences were not signi cant [8]. Furthermore, MGMT expression is heterogeneous and varies depending on the assay, and the site and timing of the assay [36,37]. Suggesting that long-term treatment with TMZ contributes to improvement of PFS and OS may thus be acceptable.…”

Section: Discussionmentioning

confidence: 99%

Combination Chemoradiotherapy with Temozolomide, Vincristine, and Interferon-β Might Improve Outcomes Regardless of O6-Methyl-Guanine-DNA-Methyltransferase (MGMT) Promoter Methylation Status in Newly Glioblastoma

Asano

Fumoto

Hasegawa

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: This investigator-initiated, open-label, single-arm, single-institute study was conducted to investigate the effectiveness of induction combination chemoradiotherapy for newly glioblastoma and also the effectiveness of long-term maintenance therapy with temozolomide (TMZ) plus interferon (IFN)-b. Methods: The initial induction combination chemoradiotherapy comprised radiotherapy plus TMZ plus vincristine plus IFN-b. Maintenance chemotherapy comprised monthly TMZ, continued for 24–50 cycles, plus weekly IFN-b continued for as long as possible. The primary endpoint was 2-year overall survival (2y-OS). A 2y-OS exceeding 38%, with upper limit of the 95% confidence interval (CI) exceeding 31.7%, and lower limit of the 95%CI exceeding 21.2% as compared to historical controls, was considered as the criterion for treatment effectiveness. Secondary endpoints were median progression-free survival (mPFS), median OS (mOS), 5-year OS rate (5y-OS), and mPFS and mOS classified according to MGMT promoter methylation status. Results: Forty-seven patients were analyzed. The 2y-OS was 40.7% (95%CI, 27.5–55.4%), suggesting that this protocol was effective. The mPFS and mOS were 11.0 months and 18.0 months, respectively, and 5y-OS was 20.3% (95%CI, 11.0–34.6%). The mPFS in groups with and without MGMT promoter methylation in the tumor was 10.0 months and 11.0 months (p=0.59), respectively, and mOS was 24.0 months and 18.0 months (p=0.88), respectively. The frequency of grade 3/4 neutropenia was 19.1%.Conclusions: These results suggest the efficacy of induction multicombination chemoradiotherapy, as well as of long-term maintenance therapy comprising TMZ plus IFN-b. This protocol would have the possibility to deny the MGMT promoter methylation status as prognostic factors.Trial registration: The University Hospital Medical Information Network (Number UMIN000040599)

show abstract

“…The IDH mutation status was determined by immunohistochemistry and pyrosequencing, the Ki67 status by immunohistochemistry and the MGMT promoter methylation status by high resolution melting real-time polymerase chain reaction. Since some of the specimens were already analyzed for a previous project, the methodology has been described in detail elsewhere [ 23 , 24 ].…”

Section: Methodsmentioning

confidence: 99%

Monopolar Spindle 1 Kinase (MPS1/TTK) mRNA Expression is Associated with Earlier Development of Clinical Symptoms, Tumor Aggressiveness and Survival of Glioma Patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

Inhibition of the protein kinase MPS1, a mitotic spindle-checkpoint regulator, reinforces the effects of multiple therapies against glioblastoma multiforme (GBM) in experimental settings. We analyzed MPS1 mRNA-expression in gliomas WHO grade II, III and in clinical subgroups of GBM. Data were obtained by qPCR analysis of tumor and healthy brain specimens and correlated with the patients’ clinical data. MPS1 was overexpressed in all gliomas on an mRNA level (ANOVA, p < 0.01) and correlated with tumor aggressiveness. We explain previously published conflicting results on survival: high MPS1 was associated with poorer long term survival when all gliomas were analyzed combined in one group (Cox regression: t < 24 months, p = 0.009, Hazard ratio: 8.0, 95% CI: 1.7–38.4), with poorer survival solely in low-grade gliomas (LogRank: p = 0.02, Cox regression: p = 0.06, Hazard-Ratio: 8.0, 95% CI: 0.9–66.7), but not in GBM (LogRank: p > 0.05). This might be due to their lower tumor volume at the therapy start. GBM patients with high MPS1 mRNA-expression developed clinical symptoms at an earlier stage. This, however, did not benefit their overall survival, most likely due to the more aggressive tumor growth. Since MPS1 mRNA-expression in gliomas was enhanced with increasing tumor aggressiveness, patients with the worst outcome might benefit best from a treatment directed against MPS1.

show abstract

Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma—A New Disease Biomarker?

Cited by 23 publications

References 48 publications

Overexpressed MPS-1 contributes to endometrioma development through the NF-κB signaling pathway

Overexpressed MPS-1 contributes to endometrioma development through the NF-κB signaling pathway

Combination Chemoradiotherapy with Temozolomide, Vincristine, and Interferon-β Might Improve Outcomes Regardless of O6-Methyl-Guanine-DNA-Methyltransferase (MGMT) Promoter Methylation Status in Newly Glioblastoma

Monopolar Spindle 1 Kinase (MPS1/TTK) mRNA Expression is Associated with Earlier Development of Clinical Symptoms, Tumor Aggressiveness and Survival of Glioma Patients

Contact Info

Product

Resources

About